Genmab A/S Website

Genmab A/S

CPSE-GMAB

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

  • Name

    Genmab A/S

  • CEO

    Jan van de Winkel

  • Website

    www.genmab.com

  • Sector

    Biotechnology

  • Year Founded

    1998

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.

  • Future therapies in multiple myeloma may complement Darzalex in combination treatments rather than competing head to head.

  • The differentiated approach of Genmab's DuoBody and HexaBody technology platforms will continue to churn out new candidates in oncology.

Bears Say

  • The multiple myeloma market is crowded with other molecules, including immunomodulatory drugs, proteasome inhibitors, HDAC inhibitors, and other targeted therapies.

  • Genmab depends heavily on its Darzalex program, making it vulnerable to competitive threats from emerging therapies in multiple myeloma, such as CAR-T and bispecifics.

  • Genmab's bispecific antibody platform is relatively unproven, with candidates in early stages of development.

Source: Morningstar Analysis - Nov 07, 2025

What's happening

Nov 8, 2025 - Dec 9, 2025

Genmab A/S Surges 10.7% Amid Strategic Advances in Oncology

  • FDA approval of epcoritamab-bysp (Epkinly) boosts investor confidence despite initial volatility.
  • $2.5 billion debt offering signals commitment to strategic acquisitions and growth initiatives.
  • Ongoing commercialization efforts for Tivdak and upcoming launches reflect proactive market positioning.

Over the past month, Genmab A/S (GMAB) experienced a significant increase of 10.7% in its stock price, outperforming the S&P 500's return of 2.2%. This performance was driven by several bullish developments that highlighted the company's strategic focus on oncology and drug development.

A key event was the FDA's approval of epcoritamab-bysp (Epkinly) for treating relapsed or refractory follicular lymphoma, which initially caused some stock volatility but ultimately reinforced investor confidence due to promising clinical results. The combination therapy showed substantial efficacy in reducing disease progression risk compared to standard treatments. Following an initial bearish reaction after this announcement on November 18, subsequent news about Genmab’s late-stage drug programs helped stabilize and enhance GMAB's stock performance.

Additionally, Genmab announced a $2.5 billion debt offering aimed at financing its acquisition of Merus N.V., which investors viewed positively as it indicates a commitment to expanding its therapeutic portfolio through strategic acquisitions. This financing strategy included senior secured notes and a term loan facility designed to support future growth initiatives while enhancing GMAB’s presence in oncology.

Genmab also emphasized ongoing commercialization efforts for Tivdak across key European markets while preparing for upcoming product launches like Rina-S projected over the next year and a half. These developments demonstrate Genmab’s proactive approach towards solidifying its position within gynecological oncology while addressing unmet medical needs.

Overall, GMAB not only outperformed broader market indices but also exceeded expectations within the Health Care sector by 7.1%, showcasing strong momentum driven by regulatory approvals and strategic financial maneuvers that align with long-term growth objectives relative to an overperformance of 8.6% against the S&P 500.

CPSE:GMAB